Dance Biopharm's Adagio inhaled insulin passes PhI/II; ANI, Sofgen team up for oral soft gel cardiovascular treatment;

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Dance Biopharm welcomed Phase I/II clinical data for its Adagio inhalable insulin candidate for Type 1 diabetes. Release

> ANI Pharmaceuticals ($ANIP) teamed up with Sofgen Pharmaceuticals to develop an oral soft gel to treat cardiovascular diseases. Release

> Researchers at the RIKEN Center for Emergent Matter Science and the University of Tokyo are leading the development of a nanomed that uses energy levels to control the delivery of a therapeutic payload. Article

> TherapeuticsMD began a Phase I study of its estradiol VagiCap to deliver hormone supplements to treat vulvar and vaginal atrophy. Release

> XstalBio launched its CentuRecon delivery tech for highly concentrated biologic drugs prepared in minutes rather than hours. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.